Ekso Bionics (NASDAQ:EKSO) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report issued on Friday. The brokerage set a “hold” rating on the stock.

EKSO has been the topic of several other reports. Lake Street Capital assumed coverage on shares of Ekso Bionics in a report on Monday, June 24th. They set a “buy” rating and a $2.50 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Ekso Bionics in a report on Tuesday, July 30th.

Ekso Bionics Trading Up 1.9 %

Shares of EKSO opened at $1.05 on Friday. Ekso Bionics has a twelve month low of $0.75 and a twelve month high of $3.13. The company has a market cap of $19.08 million, a P/E ratio of -1.08 and a beta of 1.45. The company has a current ratio of 2.42, a quick ratio of 1.77 and a debt-to-equity ratio of 0.36. The company’s fifty day simple moving average is $1.09 and its 200-day simple moving average is $1.17.

Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Monday, July 29th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Ekso Bionics had a negative net margin of 68.41% and a negative return on equity of 92.08%. The firm had revenue of $4.95 million during the quarter, compared to analysts’ expectations of $5.34 million. During the same period in the prior year, the company posted ($0.31) EPS. As a group, analysts expect that Ekso Bionics will post -0.42 EPS for the current year.

Institutional Investors Weigh In On Ekso Bionics

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC boosted its stake in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 596,050 shares of the company’s stock after buying an additional 454,892 shares during the period. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 at the end of the most recent quarter. Institutional investors own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.